RxDoctor Payments Data

Sarah Raymond

Family · Haverhill, MANPI 1164024931

Payments from drug & device makers

$564in general payments, 2019–2025

Across 15 payments — averaging $37.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$193
  • Regeneron Healthcare Solutions, Inc.$109
  • Johnson & Johnson$59
  • Capsovision, Inc.$26
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$25
  • Ardelyx, Inc.$24
  • plus $128 from 6 others

What the payments were for

  • Food & beverage$564100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$564 in reported general payments places this provider in the 70th percentile of 2,320 family providers in Massachusetts.

See all family providers in Massachusetts

Medicare billing

Part B allowed, 2024
$157
Medicare patients
14
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin16$20,052
OzempicSemaglutide11$10,075
LantusInsulin Glargine,hum.Rec.Anlog13$978
Colchicine14$600
Omeprazole19$497
Atorvastatin Calcium42$407
Metoprolol Succinate17$381
Famotidine30$315
Oxycodone Hcl15$283
Oxybutynin Chloride14$274
Amlodipine Besylate37$267
Lisinopril29$240
Metformin Hcl15$223
Tamsulosin Hcl16$205
FenofibrateFenofibrate,micronized13$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$24$10,07511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,320 family providers in Massachusetts.

Other family in Haverhill

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →